TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Swedish Orphan Biovitrum AB (publ)
Closing information (x1000 EUR)
Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Turnover | 1,993,782 | 1,688,488 | 1,518,446 |
Financial expenses | 104,722 | 44,661 | 44,393 |
Earnings before taxes | 266,222 | 298,428 | 322,190 |
EBITDA | 651,947 | 546,984 | 560,580 |
Total assets | 6,671,503 | 4,717,342 | 4,758,138 |
Current assets | 1,141,943 | 1,007,432 | 858,325 |
Current liabilities | 1,720,890 | 1,335,065 | 856,662 |
Equity capital | 3,052,181 | 2,383,563 | 2,268,820 |
- share capital | 17,484 | 15,276 | 16,525 |
Employees (average) | 1,772 | 1,556 | 1,559 |
Financial ratios
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Solvency | 45.7% | 50.5% | 47.7% |
Turnover per employee | 1,125 | 1,085 | 974 |
Profit as a percentage of turnover | 13.4% | 17.7% | 21.2% |
Return on assets (ROA) | 5.6% | 7.3% | 7.7% |
Current ratio | 66.4% | 75.5% | 100.2% |
Return on equity (ROE) | 8.7% | 12.5% | 14.2% |
Change turnover | 300,379 | 293,037 | 26,205 |
Change turnover % | 18% | 21% | 2% |
Chg. No. of employees | 216 | -3 | 50 |
Chg. No. of employees % | 14% | 0% | 3% |
Total value of public sale
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.